Advanced Enzyme Infuses ₹2.5 Million into Wholly-Owned Subsidiary ANPL

Advanced Enzyme Technologies Limited has made an additional investment of ₹2.5 million in its wholly-owned subsidiary, Advanced Nutrazyme Private Limited (ANPL). The capital infusion was executed through the subscription of a rights issue comprising 2,50,000 equity shares with a face value of ₹10 each. Post-Investment Position: Following this transaction, Advanced Enzyme's total investment in ANPL has increased to ₹3 million, bringing its total shareholding to 3,00,000 equity shares. Strategic Context: Internal Restructuring: As ANPL is already a 100% subsidiary, this rights issue does not alter the ownership structure or control. Balance Sheet Strengthening: The move is designed to bolster the subsidiary's financial position, providing it with the necessary capital to support its operational requirements and growth initiatives in the specialized nutrazyme segment. Consolidated Impact: Being an internal transfer of funds, this transaction will not materially impact Advanced Enzyme's consolidated financial statements. Outlook: This routine capital injection underscores the parent company's continued financial commitment to ANPL's strategic roadmap. Investors will view this as a standard operational funding exercise aimed at scaling the subsidiary's business capabilities. $ADVENZYMES